• Alexander Kohlmann, Vera Grossmann, Niroshan Nadarajah, and Torsten Haferlach.
• MLL Munich Leukaemia Laboratory, Munich, Germany. alexander.kohlmann@mll.com
• Br. J. Haematol. 2013 Mar 1; 160 (6): 736-53.

AbstractNext-generation sequencing platforms have evolved to provide an accurate and comprehensive means for the detection of molecular mutations in heterogeneous tumour specimens. Here, we review the feasibility and practicality of this novel laboratory technology. In particular, we focus on the utility of next-generation sequencing technology in characterizing haematological neoplasms and the landmark findings in key haematological malignancies. We also discuss deep-sequencing strategies to analyse the constantly increasing number of molecular markers applied for disease classification, patient stratification and individualized monitoring of minimal residual disease. Although many facets of this assay need to be taken into account, amplicon deep-sequencing has already demonstrated a promising technical performance and is being continuously developed towards routine application in diagnostic laboratories so that an impact on clinical practice can be achieved.© 2013 Blackwell Publishing Ltd.

12 keywords...

hide…